Intensive monitoring of adverse drug reactions in hospitalized patients of two medical units at a tertiary care teaching hospital

Journal of Pharmacology and Pharmacotherapeutics

Volumn 3, Issue 4, 2012, Pages 308-313

  Doshi, Maulik S ^a   Patel, Prakruti P ^b   Shah, Samidh P ^b   Dikshit, Ram K ^b  

^a KEM HOSPITAL   (India)

^b B J MEDICAL COLLEGE   (India)

Author keywords

Adverse drug reaction; economic impact; intensive monitoring; preventability

Indexed keywords

ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; CARDIOVASCULAR AGENT; DIGOXIN; DIURETIC AGENT; EFAVIRENZ; ENALAPRIL; FUROSEMIDE; GLYCERYL TRINITRATE; INSULIN; IPRATROPIUM BROMIDE; IRON; ISONIAZID; LACTULOSE; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; RIFAMPICIN; SALBUTAMOL; VITAMIN;

ADVERSE OUTCOME; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG MONITORING; DRUG SAFETY; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITAL PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PATIENT MONITORING; TEACHING HOSPITAL; TERTIARY HEALTH CARE; UNSPECIFIED SIDE EFFECT;

EID: 84873189815     PISSN: 0976500X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0976-500X.103687     Document Type: Article

References (22)

1. World Health Organization (WHO). The Importance on Pharmacovigilance. Safety Monitoring on Medicinal Products. Geneva (Switzerland): Office of Publications, World Health Organization; 2002.
2. Einarson TR. Drug-related hospital admissions. Ann Pharmacother 1993;27:832-8.
3. Lazarous J, Pomeranz BH, Corey PN. Incidence of Adverse drug reactions in hospitalized patients. JAMA 1998;279:1200-5.
4. Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 1998;45:301-8.
5. Dikshit RK, Desai CK, Desai MK. Pleasures and pains of running a pharmacovigilance center. Indian J Pharmacol 2008;40 (Suppl 1):s31-3.
6. Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK. Adverse drug reactions. BMJ 1998;316:1295-8.
7. Storm BL, Kimmel SE. Text book of pharmacoepidemiology. 4th ed. England: John Willey and Sons, Ltd.; 2007. p. 432-8.
8. Incidence of adverse drug reactions, India: [Last cited on 2011 Sep 26]. Available from: http://pharmacovigilance.co.in/resources/Incidence%20 of%20ADR%20india%20R1.htm
9. World health organisation. Sweden: [Last cited on 2010 Nov 12]. Available from: http://www.who-umc.org
10. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
11. Lau PM, Stewart K, Dooley MJ. Comment: Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2003;37:303-5.
12. Hartwig S, Seigel J, Schneider PJ. Preventability and severity assessment inreporting adverse drug reactions. Am J Hosp Pharm 1992;49:2229-32.
13. Ramesh M, Pandit J, Parthasarathi G. Adverse drug reactions in a south Indian hospital - their severity and cost involved. Pharmacoepidemiol Drug Saf 2003;12:687-92.
14. Fattinger K, Roos M, Vergeres P, Holenstein C, Kind B, Masche U, et al. Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal medicine. Br J Clin Pharmacol 2000;49: 158-67.
15. Lagnaoui N, Moore N, Fach J, Longy-Boursier M, Begaud B. Adverse drug reactions in a department of systemic diseases-oriented internal medicine: Prevalence, incidence, direct costs and avoidability. Eur J Clin Pharmacol 2000;55:181-6.
16. Jose J, Rao PG. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital. Pharmacol Res 2006;54:226-33.
17. Gor AP, Desai SV. Adverse Drug Reactions (ADR) in the inpatients of Medicine Department of a Rural Tertiary Care Teaching Hospital and Influence of Pharmacovigilance in Reporting ADR. Indian J Pharmacol 2008;40:37-40.
18. Hurwitz N, Wade OL. Intensive hospital monitoring of adverse reactions to drugs. BMJ 1969;1:531-6.
19. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events and potential adverse drug events: Implications for prevention JAMA 1995;274:29-34.
20. Dormann H, Neubert A, Criegee-Rieck M, Egger T, Radespiel-TröGer M, Azaz-Livshits T, et al. Readmissions and adverse drug reactions in internal medicine: The economic impact. J Intern Med 2004;255:653-63.
21. Faich GA. US Adverse Drug Reaction Surveillance 1989-1994. Pharmacoepidemiol Drug Saf 1996;5:393-8.
22. Patel KJ, Kedia MS, Bajpai D, Mehta SS, Kshirsagar NA, Gogtay NJ. Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: A prospective study. BMC Clin Pharmacol 2007;7:8.